Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
== Other uses == Clash Royale, a popular mobile strategy game developed and published by Supercell Challenge rating, a rating of challenges in Dungeons & Dragons Chart Rulership or Chart Ruler, in astrology Comfort room, another name for a public toilet Consciousness raising, in social activism Continuing resolution, a type of appropriations legislation in the US Councillor, a title for a public servant, used in Australia and New Zealand Cree language (ISO 639 alpha-2 code CR) Critical reading, a skill measured by the Scholastic Aptitude Test (SAT) Critical Role, a Dungeons & Dragons show Critical Role Productions, the associated media production company Crore, a number representing 10,000,000 in the Hindu-Arabic numeral system Crunchyroll, internet streaming service showing anime Cr$ or ₢, symbol for Brazilian cruzeiro
There had been Jewish tribes in Aden and Yemen for millennia, where they had primarily constituted the artisans and craftsmen of these areas, but it was after the British occupation of 1839 that Aden became an important congregation. During the two World Wars the Jews in Aden had prospered while those in Yemen suffered. The Balfour Declaration had encouraged increased Jewish immigration into the Holy Land, and as a result many of the Jewish communities from all over the Middle East sought a new home there. The Palestine issue had a serious effect on British prestige in Aden. During the Second World War, Jews from Yemen flocked in large numbers into Aden while en route to Mandatory Palestine, where they were placed in refugee camps, primarily for their own safety. However conditions in the camps were difficult and in 1942 there was an outbreak of typhus. The outbreak of the anti-Jewish riots in December 1947, following the UN declaration for the creation of a Jewish state, left at least 70 Jews were killed and much of the Jewish Quarter burned and looted. Until this point nearly all the refugees had been from Yemen and the Aden Protectorate, but now after the growing violence against Jews in the Town itself, most tried to leave. The riots left the Jewish community with the sense that their personal safety and long-term financial security were at risk, with more than 2,800 Jewish residents having left Aden and made it to Israel by 1950. Population figures which showed roughly 4,500 Jews in 1947 had dropped to less than 500 in 1963.
Shorter D-stem: To understand the role of the unusual long D-stem in tRNASec, artificial variants with shorter D-stems were put into E. coli. It turns out that these variants work faster than the standard version at regular temperatures but easily lose function at high temperatures. This suggests that the long D-stem evolved as an adaptation to high temperature. Removal of SelB and SECIS requirement: In 2013, a new kind of tRNA was artificially created by putting the acceptor stem and CUA anticodon of E. coli tRNASec on the backbone of E. coli tRNASer. This new tRNAUTu can be recognized by ordinary EF-Tu, removing the requirement for SelB and SECIS for elongation. However, about 40% of the insertions were serine instead of selenocystine, suggesting that SelA is not efficiently recognizing this tRNA. In 2014, directed evolution was used to greatly improve the ability of tRNAUTu to be recognized by SelA, achieving a version that results in no detected misincorporation of serine. This enables simple replacement of any residue by Sec in future protein engineering efforts. By 2018, the E. coli system has matured to be suitable for "industrial scale" production. In one case this was achieved by laborotaory evolution. In another case this was achieved by incorporating elements of allo-tRNAs. The tRNAUTu system was adapted to Saccharomyces cerevisiae (yeast), which has no natural selenocystine system, in 2023. A mixture of bacterial and mouse enzymes work on a modified yeast tRNASer, which is able to be recognized by eEF1A.
TSAVLQ-SGFRK-NH2 and SGVTFQ-GKFKK are the two peptides corresponding to the two self-cleavage sites of the SARS 3C-like proteinase The protease is important in the processing of the coronavirus replicase polyprotein (P0C6U8). It is the main protease in coronaviruses and corresponds to nonstructural protein 5 (nsp5). It cleaves the coronavirus polyprotein at 11 conserved sites. The 3CL protease has a cysteine-histidine catalytic dyad at its active site. The sulfur of the cysteine acts as a nucleophile and the imidazole ring of the histidine as a general base.
Sources: en.wikipedia.org
The Supreme Court then ruled to remove the words "by blood" from its constitution and other legal doctrines because "[t]he words, added to the constitution in 2007, have been used to exclude Black people whose ancestors were enslaved by the tribe from obtaining full Cherokee Nation citizenship rights." However, all citizenship is still based on finding an ancestor tied to the Dawes Rolls, which is not without its own controversy apart from blood quantum. Some people of descent are still excluded, like the author Shonda Buchanan who states in her memoir Black Indian that she has ancestors on Cherokee Rolls that were not the Dawes, so would thus still not be recognized. The changes to the Cherokee Nation constitution are still being challenged after the change, most recently by Robin Mayes who appealed for a new election. On September 13, 2021, Marilyn Vann became the first Cherokee Freedmen descendant to be confirmed to a Cherokee government commission when she was appointed to the Environmental Protection Commission by Principal Chief Chuck Hoskin Jr.
== See also == All pages with titles containing Link Linc (disambiguation) Lincs (disambiguation) Linker (disambiguation) Linq (disambiguation) Linx (disambiguation) Lynx (disambiguation) Microsoft Lync Linkt, road tolling brand in Australia
=== Embryonic pluripotency === The Elabela protein is synthesized, processed and secreted by undifferentiated human embryonic stem cells but not mouse embryonic stem cells. In humans it is under the direct regulation of POU5F1 (a.k.a. OCT4) and NANOG. Through autocrine and paracrine signalling, endogenous Elabela entrains the PI3K/AKT/mTOR pathway to maintain pluripotency and self-renewal.
Members of this family are found in birds, fish, reptiles and amphibians (mesotocin, isotocin, valitocin, glumitocin, aspargtocin, vasotocin, seritocin, asvatocin, phasvatocin), in worms (annetocin, nematocin), octopuses (cephalotocin, octopressin), insects (locupressin, inotocin) and in molluscs (conopressins G and S). Animals that lack a hormone from this family include fruit flies, and at least some mosquitos, silkworms, and honeybees.
De novo gene birth is the process by which new genes evolve from non-coding DNA. De novo genes represent a subset of novel genes, and may be protein-coding or instead act as RNA genes. The processes that govern de novo gene birth are not well understood, although several models exist that describe possible mechanisms by which de novo gene birth may occur. Ancient de novo gene birth events are difficult to detect. Most studies of de novo genes to date have thus focused on young genes, typically taxonomically restricted genes (TRGs) that are present in a single species or lineage, including so-called orphan genes, defined as genes that lack any identifiable homolog. Not all orphan genes arise de novo, but rather through fairly well characterized mechanisms such as gene duplication (including retroposition) or horizontal gene transfer followed by sequence divergence, or by gene fission/fusion. Although de novo gene birth was once viewed as a highly unlikely occurrence, thousands of examples have now been described, and some researchers speculate that de novo gene birth could play a major role in evolutionary innovation, morphological specification, and adaptation, probably promoted by their low level of pleiotropy. Conversely, criticism of the methodology and interpretation used to identify de novo gene candidates has appeared in the literature, including arguments that some reported cases may reflect artefacts of homology detection and annotation rather than genuine novelty.
Sources: en.wikipedia.org
=== D.J. Conner === David Jacob "D.J." Conner is played by Michael Fishman (Sal Barone in the pilot episode). Born in 1981, David, better known by his initials D.J., is the youngest of Roseanne and Dan's children and their only son until the birth of Jerry Conner, in 1995. It is noted that D.J. does well in school, though he seems less intellectually astute than Darlene and Becky. He is naïve and more boisterous than his older sisters, who frequently taunt him. In the first episode of Season 3, it is stated that while Becky and Darlene were planned pregnancies, D.J. was a "surprise". As he grows older, D.J.'s storylines deal with more mature topics such as masturbation, sexuality, racism, child abuse, and religion. A growing rebelliousness leads him to become increasingly disrespectful, skipping school, and engaging in other minor mischiefs. When D.J., not yet a teenager, steals and wrecks the family car in Season 6, Roseanne's uncontrolled anger results in her severely hitting him. Later episodes depict D.J. developing a brotherly bond with Becky's husband Mark, who often dispenses incorrect or inappropriate advice. D.J. later shows an artistic side and develops an interest in filmmaking. He wants to videotape Darlene giving birth but continually faints while attempting to watch a childbirth video to prepare. He was among the few characters whose storylines were unaltered in the final episode of Season 9, which has since been ret-conned out of existence. In Season 10, D.J. recently retired from the military and returned home after serving in Syria.
=== Pharmacodynamics === Cyclofenil is a SERM, or a mixed agonist and antagonist of the estrogen receptors (ERs). It is described as a relatively weak/mild SERM. The medication is generally less effective than other SERMs. The medication is an "impeded estrogen" and is thought to work as a progonadotropin by blocking the actions of estrogens in the pituitary gland and hypothalamus, thereby disinhibiting release of the gonadotropins luteinizing hormone and follicle-stimulating hormone. In men, cyclofenil can increase testosterone levels due its progonadotropic effects.
Beta-peptides (β-peptides) are peptides derived from β-amino acids, in which the amino group is attached to the β-carbon (i.e. the carbon two atoms away from the carboxylate group). The parent β-amino acid is β-alanine (H2NCH2CH2CO2H), a common natural substance, but most examples feature substituents in place of one or more C-H bonds. β-peptides usually do not occur in nature. β-Peptide-based antibiotics are being explored as ways of evading antibiotic resistance. Early studies in this field were published in 1996 by the group of Dieter Seebach and that of Samuel Gellman.
=== Thorium-231 === 231Th has 141 neutrons. It is the decay product of uranium-235. It is found in very small amounts on the earth and has a half-life of 25.52 hours. When it decays, it emits a beta ray and forms protactinium-231, with a decay energy of 0.39 MeV.
In nuclear physics, transient equilibrium is a situation in which equilibrium is reached by a parent-daughter radioactive isotope pair where the half-life of the daughter is shorter than the half-life of the parent. Contrary to secular equilibrium, the half-life of the daughter is not negligible compared to parent's half-life. An example of this is a molybdenum-99 generator producing technetium-99 for nuclear medicine diagnostic procedures. Such a generator is sometimes called a cow because the daughter product, in this case technetium-99, is milked at regular intervals. Transient equilibrium occurs after four half-lives, on average.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.